Numerous individuals worldwide grapple with chronic diseases, facing a lack of authorized medicines within their home countries. These patients may have exhausted all commercially available intensive treatments, lack access to clinical trials, or reside in regions where crucial drugs are unavailable through conventional commercial channels.

Headquartered in Australia, Special Access Pharma plays a pivotal role in assisting healthcare professionals and patients. We facilitate access to potentially life-saving medicines that are unlicensed or otherwise inaccessible to them via an established Named Patient Supply process.

What is Named Patient Supply?

Named Patient Supply, also known as the special access scheme, expanded/early access program, or compassionate use program, serves as a mechanism enabling specific healthcare professionals to access unlicensed products or medicines that have been approved or are nearing approval in other countries. This occurs before receiving marketing authorization in their home country, and it is intended for the treatment of individual patients. Each country has its own regulations establishing a framework to facilitate access to these medicinal products for patients in need. The specific requirements for utilization may differ from one country to another.

Through Named Patient Supply, healthcare professionals can ethically and legally prescribe medications, ensuring patients have access to the best available treatments tailored to their individual needs.

Special Access Pharma supports Named Patient Supply for medicines that fall into the following categories:

• 1. Not Registered in the Country: Medicines that are approved in one country but not registered in another, allowing patients in the latter to access these approved treatments.
• 2. Licensed Medicine Unsuitability: Situations where a licensed medicine is available, but it is unsuitable for the patient, necessitating access to alternative treatments through Named Patient Supply.
• 3. Clinical Trial Access: Medicines still in clinical trials, awaiting official approval, providing patients with the opportunity to access potential life-saving treatments before they are widely available.
• 4. Value for Small Patient Groups: Medicines that may never receive broad approval but offer substantial value for a small patient group, such as orphan drugs for rare diseases.
• 5. Discontinued and Unregistered: Medicines that have been discontinued and are no longer registered, ensuring access for patients who may still benefit from their use.

By addressing these diverse scenarios, Special Access Pharma aims to ensure that patients and healthcare professionals have access to a comprehensive range of medicines tailored to individual needs.